Mortality Similar for Prostate Cancer Therapies.
The UK-based ProtecT trial reports that, after a median of 10 years of follow up, there is no significant difference in prostate cancer-specific mortality between active monitoring, surgery, and radiotherapy. However, the likelihood of developing metastases is more than twice as great with active monitoring compared with treatment.